DRG 645 Overview

DRG 645 covers inpatient admissions for endocrine disorders without a Complication or Comorbidity or Major Complication or Comorbidity, including primary diagnoses such as uncontrolled diabetes without additional systemic complications, thyroid disorders, and adrenal or pituitary conditions managed during a single hospital stay. This Diagnosis-Related Group groups cases with relatively lower expected resource use compared with endocrine cases that include complications, which affects relative payment under Medicare inpatient prospective payment systems. The classification impacts hospital reimbursement, length-of-stay expectations, and case-mix reporting for Centers for Medicare & Medicaid Services payment determinations.

• Acute endocrinology intervention trials: randomized or prospective studies testing short-term inpatient interventions for acute metabolic decompensations (for example, protocols for faster correction of severe hyperglycemia, thyroid storm stabilization pathways, or adrenal crisis management bundles). These studies enroll patients admitted with acute endocrine emergencies or severe exacerbations of chronic endocrine disease, comparing different timing, monitoring strategies, or supportive therapies to reduce time to biochemical control and length of stay. Results inform hospital protocols and utilization management by identifying interventions that safely shorten admissions or reduce complication rates, which affects resource use and payer costs.
• Comparative effectiveness studies for inpatient management strategies: pragmatic trials or observational comparative-effectiveness research evaluating different in-hospital care models or therapeutic algorithms for common noncritical endocrine diagnoses (for example, medication choice and titration strategies for hospitalized patients with poorly controlled diabetes, or pathways for new-onset hypothyroidism identified during admission). These studies focus on typical adult inpatient populations without major complications (the DRG without CC/MCC), assessing outcomes such as glycemic excursions, readmission rates, and discharge medication accuracy. Findings help clinicians and payers determine which standard-of-care approaches produce better short-term outcomes and lower downstream utilization across diverse hospital settings.
• Post-discharge outcomes and transitions-of-care research: cohort studies and implementation research examining discharge planning, outpatient follow-up, and care coordination for patients admitted for endocrine disorders without complications — for example, interventions to improve outpatient endocrinology follow-up, medication reconciliation, education on self-management, and remote monitoring after discharge. These studies target the transition period to reduce early readmissions, emergency visits, and medication-related errors among patients who are clinically stable at discharge. Insights are relevant to providers and payers because effective transition interventions can reduce avoidable resource use and improve long-term disease control, impacting readmission metrics and overall cost of care.